Key Takeaways:
- ISRG reported Q2 2026 earnings with moderated US procedure growth.
- The company guided to its slowest growth in years, sending shares lower.
- China remained a challenging market while global platform adoption continued.
Back
Intuitive Surgical slides 12% as guidance signals slowest growth in years
Intuitive Surgical reported Q2 results with moderated US procedure growth, sending shares down 12% after the company guided to its slowest expansion in years.
"Global adoption of our da Vinci and Ion platforms continues to expand, though we are seeing near-term moderation in US procedure volumes," management said on the earnings call.
The company did not disclose specific revenue or earnings per share figures in its preliminary highlights. China remained a challenging market, weighing on the outlook. The guidance for the slowest growth in years marked a sharp deceleration from the double-digit procedure growth the company had sustained through much of the post-pandemic period. Global adoption of the da Vinci SP single-port system and the Ion endoluminal platform continued, though management did not provide country-level breakdowns.
The 12% decline erased billions in market value for the S&P 500 component. The guidance cut signals that near-term headwinds in the US and China may persist longer than expected. Investors will focus on the full Q2 filing and the upcoming earnings call for details on procedure volume trends and the timeline for a US recovery.
This article is for informational purposes only and does not constitute investment advice.
[1] Intuitive Surgical Q2 Earnings Call Highlights[2] ClearBridge Large Cap Growth Fund Q2 2026 Commentary[3] Stocks pressured by a renewed selloff in chipmakers[4] Nasdaq, S&P 500 futures slip as Iran tensions, chip weakness keep investors on edge: Why TSM, NVDA, NFLX, ATAI, ASTS are in focus[5] Robotic surgery giant crashes after guiding to its slowest growth in years
© 2026 Finture Development Limited (Ed:Wealth). All rights reserved.